Immunocytochemical study of urine cytological preparations from secondary prostatic adenocarcinoma involving the urinary bladder

Diagnostic Cytopathology

Volumn 36, Issue 10, 2008, Pages 715-720

  Mai, Kien T ^a,b   Ahmed, Itrat ^a   Robertson, Susan J ^a   Belanger, Eric C ^a   Veinot, John P ^a   Islam, Shahid ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Carcinoma; Cytology; Prostatic; Urothelial

Indexed keywords

CYTOKERATIN; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; BLADDER METASTASIS; CELL NUCLEUS; CELL STRUCTURE; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; CYTOPLASM; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE ADENOCARCINOMA; RETROSPECTIVE STUDY; SMEAR; URINE CYTOLOGY; UROGENITAL TRACT TUMOR; UROTHELIUM;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; MALE; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS; URINE;

EID: 53049084173     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.20886     Document Type: Article

References (15)

1. Mai KT, Ford JC, Morash C, Gerridzen R. Primary and secondary prostatic adenocarcinoma of the urinary bladder. Hum Pathol; 2001;32:434-440.
2. Martínez-Rodríguez M, Ramos D, Soriano P, Subramaniam M, Navarro S, Llombart-Bosch A. Poorly differentiated adenocarcinomas of prostate versus high-grade urothelial carcinoma of the bladder: A diagnostic dilemma with immunohistochemical evaluation of 2 cases. Int J Surg Pathol 2007;6:213-218.
3. Genega EM, Hutchinson B, Reuter VE, Gaudin PB. Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma. Mod Pathol 2000;11:1186-1191.
4. Pelte MF. Immunohistochemical profile of high-grade urothelial bladder carcinoma and prostate adenocarcinoma. Hum Pathol 2002;33:1136-1140.
5. Mai KT, Collins JP, Veinot JP. Prostatic adenocarcinoma with urothelial (transitional cell) carcinoma features. Appl Immunohistochem Mol Morphol 2002;10:231-236.
6. Varma M, Morgan M, Amin MB. High molecular weight cytokeratin antibody (clone 34βE12): A sensitive marker for differentiation of high-grade invasive urothelial carcinoma from prostate cancer. Histopathology 2004;45:98-99.
7. Kunju LP, Mehra R, Snyder M, Shah RB. Prostate-specific antigen, high-molecular-weight cytokeratin (clone 34βE12), and/or p63: An optimal immunohistochemical panel to distinguish poorly differentiated prostate adenocarcinoma from urothelial carcinoma. Am J Clin Pathol 2006;125:675-681.
8. Genega EM, Hutchinson B, Reuter VE, Gaudin PB. Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma. Mod Pathol 2000;13:1186-1191.
9. Mhawech P, Uchida T, Pelte MF. Immunohistochemical profile of high-grade urothelial bladder carcinoma and prostate adenocarcinoma. Hum Pathol 2002;33:1136-1140.
10. Singh A, Kinoshita Y, Rovito PM, Jr. Higher than expected association of clinical prostate and bladder cancers. J Urol 2005;173;1526-1529.
11. Krishnan B, Truong LD. Prostatic adenocarcinoma diagnosed by urinary cytology. Am J Clin Pathol 2000;113:29-34.
12. Varma VA, Fekete PS, Franks MJ, Walther MM. Cytologic features of prostatic adenocarcinoma in urine: A clinicopathologic and immunocytochemical study. Diagn Cytopathol 1988;4:300-305.
13. Rupp M, O'Hara B, McCullough L, Saxena S, Olchiewski J. Prostatic carcinoma cells in urine specimens. Cytopathology 1994;5:164-170.
14. Bhatia A, Dey P, Kumar Y, et al. Expression of cytokeratin 20 in urine cytology smears: A potential marker for the detection of urothelial carcinoma. Cytopathology 2007;18:84-86.
15. Siracusano S, Niccolini B, Knez R, et al. The simultaneous use of telomerase, cytokeratin 20 and CD4 for bladder cancer detection in urine. Eur Urol 2005;47:327-333.